ROC-101

DRUG2 trials

Sponsors

Allrock Bio Inc., AllRock Bio, Inc.

Conditions

Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH)Pulmonary Hypertension, Interstitial Lung Disease

Phase 2

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

RecruitingNCT07175038

AllRock Bio, Inc.Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease

Start: 2025-10-01End: 2029-03-01Target: 40Updated: 2026-08-10

A PHASE 2A, OPEN-LABEL SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)

Not yet recruitingCTIS2025-522074-37-00

Allrock Bio Inc.Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH)

Target: 21Updated: 2025-12-22